SSG
CYTH

Summit Securities Group’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

Summit Securities Group’s Portfolio CYTH Stock Details CYTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,725
Closed -$1K – 1127
2023
Q1 		$1K Buy
+1,725
New +$2.45K ﹤0.01% 762

Other funds holding CYTH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Summit Securities Group's CYTH Position: Q2 2023 in Review

Summit Securities Group sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q2 2023, closing a stake of 1,725 shares — an estimated $1K sold.

Summit Securities Group first reported a position in CYTH in Q1 2023 and held it in 1 quarter. The position peaked at $1K in Q1 2023. 14 funds tracked by Wall St. Rank hold CYTH as of Q2 2023.

  • Summit Securities Group reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Summit Securities Group sold 1,725 Cyclo Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $1K.
  • Summit Securities Group first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Summit Securities Group's Cyclo Therapeutics, Inc. Common Stock position peaked at $1K in Q1 2023.
  • 14 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Summit Securities Group's 13F filing for Q2 2023, filed 14 Aug 2023.